briacell-logo-square-a.jpg
BriaCell Announces Oral and Poster Presentations at ASCO 2024
April 24, 2024 08:00 ET | BriaCell Therapeutics Corp.
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and...
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
April 23, 2024 09:00 ET | Diamond Equity Research LLC; ProPhase Labs Inc.
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase...
Global Oncology Precision Medicine Market
Global Oncology Precision Medicine Market Trends and Forecasts Report 2024: A $364 Billion Industry by 2035 Amidst a Clinical Trials Boom with Over 6,500 Trials
April 23, 2024 04:37 ET | Research and Markets
Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The "Oncology Precision Medicine Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Cancer Targeted, Route of Administration,...
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
April 18, 2024 16:30 ET | Celularity Inc.
FLORHAM PARK, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and...
Vigil_Logo_TM (002).png
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
April 17, 2024 16:05 ET | Vigil Neuroscience, Inc.
- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology - - Positive interim IGNITE Phase 2 data demonstrating...
AskBio presents 18-m
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease
April 16, 2024 08:03 ET | Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 16, 2024 (GLOBE NEWSWIRE) --   Not intended for UK Media AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
April 15, 2024 17:01 ET | Zevra Therapeutics
The oral presentation highlighted data from Zevra’s Expanded Access Program demonstrating a consistent safety profile CELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics,...
cmi_logo.png
[Latest] Global Lung Tumor Market Size/Share Worth USD 46.3 Billion by 2033 at a 7.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 15, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, April 15, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Lung Tumor Market Size, Trends and Insights By Product (Imaging systems, Biopsy...
biomerica.png
Biomerica provides update on inFoods® IBS expansion
April 15, 2024 07:47 ET | Biomerica, Inc.
- Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in physicians prescribing inFoods more...
biomerica.png
Biomerica Reports Third Quarter 2024 Financial Results
April 12, 2024 19:23 ET | Biomerica, Inc.
Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024  InFoods IBS Positive Clinical Data to be Presented...